Table Graph
      published meta-analysis   sensitivity analysis   studies

mRNA vaccine in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 6 months symptomatic COVIDdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.09 [0.07; 0.11] 0.09[0.07; 0.11]BNT162b2 phase 3 (C4591001, Polack), 202010%46,077NAnot evaluable confirmed Covid-19, from 1st dosedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09] 0.10[0.03; 0.35]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020293%70,779moderatenot evaluable deathsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.50 [0.09; 2.73] COVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84] 0.50[0.11; 2.28]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%71,459moderatenot evaluable vaccine efficacy from randomization (ITT)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] COVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11] 0.11[0.04; 0.29]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020291%71,720moderatenot evaluable confirmed COVID (any severity)detailed resultsC4591031- first boost, 2021 0.05 [0.02; 0.13] 0.05[0.02; 0.13]C4591031- first boost, 202110%10,125NAnot evaluable symptomatic Covid-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.05 [0.02; 0.10] COVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11] 0.05[0.03; 0.09]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%64,730moderatenot evaluable 6 months severe COVID-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.03 [0.00; 0.46] 0.03[0.00; 0.46]BNT162b2 phase 3 (C4591001, Polack), 202010%NAnot evaluable severe COVID-19 (FDA definition)detailed resultsC4591031- first boost, 2021 0.25 [0.01; 5.50] 0.25[0.01; 5.50]C4591031- first boost, 202110%10,125NAnot evaluable severe COVID-19 occurrencedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.25 [0.01; 5.62] C4591031- first boost, 2021 0.25 [0.01; 5.50] COVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27] 0.09[0.01; 0.56]BNT162b2 phase 3 (C4591001, Polack), 2020, C4591031- first boost, 2021, COVE Moderna/NIH phase 3 (study 301), 2020310%80,905moderatenot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.48 [0.32; 0.71] 0.48[0.32; 0.71]BNT162b2 phase 3 (C4591001, Polack), 202010%43,355NAnot evaluable related AE (TRAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.91 [4.58; 5.26] 4.91[4.58; 5.26]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable related SAE (TRSAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 8.00 [0.42; 151.43] 8.00[0.42; 151.43]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable serious adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.14 [0.88; 1.47] COVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40] 1.10[0.90; 1.33]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%73,603moderatenot evaluable adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.62 [2.49; 2.76] Com-COV, 2021 1.14 [0.78; 1.66] COVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20] 1.52[0.78; 2.97]BNT162b2 phase 3 (C4591001, Polack), 2020, Com-COV, 2021, COVE Moderna/NIH phase 3 (study 301), 20203100%74,066lownot evaluable arrhythmiadetailed resultsC4591031- first boost, 2021 1.99 [0.07; 59.22] 1.99[0.07; 59.22]C4591031- first boost, 202110%10,075NAnot evaluable hypertensiondetailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable intracranial hemorrhage detailed resultsCom-COV, 2021 1.01 [0.02; 51.28] 1.01[0.02; 51.28]Com-COV, 202110%463NAnot evaluable ischemic strokedetailed resultsCom-COV, 2021 1.01 [0.02; 51.28] 1.01[0.02; 51.28]Com-COV, 202110%463NAnot evaluable life-threatening SAEdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.91 [0.51; 1.65] 0.91[0.51; 1.65]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable Myocardial infarction detailed resultsC4591031- first boost, 2021 0.74 [0.17; 3.33] Com-COV, 2021 1.01 [0.02; 51.28] Reindl-Schwaighofer, 2021 2.03 [0.07; 61.21] 0.89[0.24; 3.25]C4591031- first boost, 2021, Com-COV, 2021, Reindl-Schwaighofer, 202130%10,739lownot evaluable pulmonary embolismdetailed resultsC4591031- first boost, 2021 0.17 [0.01; 3.30] Com-COV, 2021 1.01 [0.02; 51.28] 0.32[0.03; 3.48]C4591031- first boost, 2021, Com-COV, 202120%10,538lownot evaluable serious adverse events (SAE), anydetailed resultsReindl-Schwaighofer, 2021 1.53 [0.25; 9.36] 1.53[0.25; 9.36]Reindl-Schwaighofer, 202110%201NAnot evaluable severe adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.74 [1.41; 2.14] 1.74[1.41; 2.14]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsC4591031- first boost, 2021 0.99 [0.06; 15.88] 0.99[0.06; 15.88]C4591031- first boost, 202110%10,075NAnot evaluable venous thromboembolism detailed resultsReindl-Schwaighofer, 2021 2.03 [0.07; 61.21] 2.03[0.07; 61.21]Reindl-Schwaighofer, 202110%201NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable appendicitisdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.00 [0.60; 6.65] C4591031- first boost, 2021 3.97 [0.18; 88.14] COVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99] 1.57[0.61; 4.04]BNT162b2 phase 3 (C4591001, Polack), 2020, C4591031- first boost, 2021, COVE Moderna/NIH phase 3 (study 301), 202030%83,874moderatenot evaluable arthralgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91] 18.37[13.54; 24.91]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable Bell's palsydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 7.99 [0.42; 151.24] COVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83] 4.32[0.72; 25.96]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%67,937moderatenot evaluable hypersensitivity, all termsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.17 [0.82; 5.71] COVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72] 1.43[1.18; 1.74]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%73,603moderatenot evaluable immediate allergic reactiondetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.00 [0.02; 50.42] 1.00[0.02; 50.42]BNT162b2 phase 3 (C4591001, Polack), 202010%43,448NAnot evaluable lymphadenopathy, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 10.69 [4.63; 24.69] 10.69[4.63; 24.69]BNT162b2 phase 3 (C4591001, Polack), 202010%37,586NAnot evaluable lymphadenopathy, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 3.65 [3.26; 4.09] COVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 3.64[3.25; 4.08]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 202020%67,937moderatenot evaluable myalgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50] 27.64[20.93; 36.50]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable fever, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10] 43.29[17.83; 105.10]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable local adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 24.90 [22.13; 28.03] 24.90[22.13; 28.03]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable local adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 23.04 [20.30; 26.15] COVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03] 27.99[19.26; 40.68]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020296%36,742moderatenot evaluable local adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12] 15.04[11.83; 19.12]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.63 [1.50; 1.78] 1.63[1.50; 1.78]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.55 [4.13; 5.01] COVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05] 5.53[3.79; 8.06]BNT162b2 phase 3 (C4591001, Polack), 2020, COVE Moderna/NIH phase 3 (study 301), 2020298%36,749moderatenot evaluable systemic adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77] 9.50[8.38; 10.77]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-05-03 23:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 806,758,826,755 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons